Table 2.
Rates of Confirmed HHEs Within 48 Hours of a First or Second Dose of Any DTaP Vaccine, KPNC 2002–2005
| Group | Dose | Doses Under Active Surveillance | Potential HHE Cases Adjudicated | Confirmed HHE | Rate (95% CI) per 100,000 Doses | Risk (95% CI) per 100,000 Children With 2 Doses |
|---|---|---|---|---|---|---|
| DTaP5 | Dose 1 | 9474 | 5 | 2 | 21.1 (2.6–76.2) | 21.1 (0.0–50.4) |
| Dose 2 | 7235 | 4 | 0 | 0.0 (0.0–51.0) | ||
| Doses 1 and 2 combined | 16,709 | 9 | 2 | 12.0 (1.5–43.2) | ||
| DTaP3 | Dose 1 | 6240 | 2 | 0 | 0.0 (0.0–59.1) | 0.00 (NA) |
| Dose 2 | 3834 | 2 | 0 | 0.0 (0.0–96.2) | ||
| Doses 1 and 2 combined | 10,074 | 4 | 0 | 0.0 (0.0–36.6) | ||
| DTaP-HBV-IPV | Dose 1 | 11,677 | 14 | 7 | 60.0 (24.1–123.5) | 81.5 (30.9–132.2) |
| Dose 2 | 13,902 | 9* | 3 | 21.6 (4.5–63.1) | ||
| Doses 1 and 2 combined | 25,579 | 23 | 10 | 39.1 (18.7–71.9) | ||
| Cross-over | Dose 2 | 169 | 0 | 0 | 0.0 (0.0–2159.1) | NA |
| Total | Dose 1 | 27,391 | 21 | 9 | 32.9 (15.0–62.4) | 44.9 (19.5–70.3) |
| Dose 2 | 25,140 | 15 | 3 | 11.9 (2.5–34.9) | ||
| Doses 1 and 2 combined | 52,531 | 36 | 12 | 22.8 (11.8–39.9) |
*An additional potential HHE case after a second dose DTaP-HBV-IPV was detected by database surveillance, referred to the panel and confirmed as HHE by 2 of the 3 panelists. The case is not included in the counts or rates in this table, which is based on active surveillance.
NA indicates not applicable.
Cross-over means any subject receiving a different DTaP at dose 2 than at dose 1.